Windlas Biotech IPO GMP Today, Subscription Status, Share Price, Dates, Review, and more

After the much hyped Glenmark Life Sciences IPO and Rolex Rings IPO, Windlas Biotech IPO has made its arrival into the Indian stock market arena with issue size of Rs 401.53 crores. It will be using the market profits for capacity expansion tools in their Dehradhun plant 4 (total 4 plants) and also for other requirements. This IPO comes with a face value of Rs 5 per equity share, fresh issue size of Rs 165 cr, and approx 5142K shares via offer-for-sale. Get to know the Windlas Biotech IPO GMP Today, Subscription Status, Share Price, Dates, Review, and more in this short read.

All the Windlas Biotech IPO Dates are now out so make a note of them so that you don’t miss out. Also, you can check Latest IPO News for recent IPO updates.

The Windlas Biotech IPO GMP is now out as the grey market for this IPO has opened. Its GMP today (5th August 2021, 11:18) is Rs 45. Thus, it has jumped (backwards) from Rs 160 GMP which was on 31st July 2021, but also gone ahead by 30 from yesterday. 

The Windlas IPO Subscription Status of day 1 says that the issue is 3.17 times oversubscribed. Considering other 3 IPOs launched along with it, Windlas IPO is a step back here.

The Windlas Biotech IPO share price is in the Rs 448-460 price band per equity share with a face value of Rs 5 per equity share.

Windlas Biotech is into development of nutraceutical, pharmaceutical and ayurvedic products. Its USP is to provide authentic & affordable products to rural and semi-urban regions of India. It is a 20-year old company and employs 954 people across its 4 manufacturing units in Dehradun, Uttarakhand. Its sales & distribution presence is in 14 states.

Check out the Windlas Biotech Company Turnover or Financials of previous years in the table below. Make a note that the values mentioned here are approximate ones.

The Windlas Biotech IPO Lot Size is 30 shares. thus, you can apply for a min of 30 and a maximum of 420 shares (14 lots). The minimum cut-off investment amount is Rs 13,800. The Windlas Biotech IPO retail quota is 35% which is great news for retail investors.

Windlas Biotech has got a good amount of experience in its field of work. Moreover, it has big clients in Pfizer, Sanofi India, Cadila Healthcare, Emcure Pharmaceuticals, Eris Lifesciences, Intas Pharmaceuticals, and Systopic Laboratories. Talking about its financials, profits have gone down but the good news is that assets and revenue are stable so can bounce back in the upcoming years. Once this IPO progresses we will get to know the anchor investors and also how it fares in the grey market so till then you can take it as a 60:40 ratio.

Disclaimer : We are not SEBI registered. The information provided herein is for education purposes only. We will not be responsible for any of your profit/loss with this channel's suggestion. Consult your financial advisor before making any decision.